Recent News

• 06.12.2025 - ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
• 06.12.2025 - ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
• 06.09.2025 - ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
• 06.09.2025 - ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
• 06.03.2025 - ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
• 06.03.2025 - ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
• 05.21.2025 - ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
• 05.21.2025 - ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

Recent Filings

• 06.09.2025 - 8-K Current report
• 06.09.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.06.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.30.2025 - 8-K Current report
• 05.30.2025 - 8-K Current report
• 05.30.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.28.2025 - EX-99.1 EX-99.1
• 05.28.2025 - 8-K Current report
• 05.20.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB